Lilly to supply up to U.S. 600,000 doses of COVID-19 treatment

Eli Lilly and Co. LLY, -1.49% said late Thursday it has inked a deal with the U.S. government to supply up to 600,000 doses of its investigational COVID-19 drug bebtelovimab for at least $720 million. The U.S. will accept the doses once the FDA grants the treatment an emergency-use authorization, the company said. Lilly has submitted a request for an EUA for bebtelovimab for the treatment of mild to moderate COVID-19 in certain high-risk patients. Shares of Lilly rose 0.3% in the extended session, after it ended the regular trading day down 1.5%.